Tirzepatide has emerged as a groundbreaking therapy for type 2 diabetes, offering promising results. However, the expense of this innovative drug and its access have become key issues for patients and healthcare providers. While tirzepatide has been approved by regulatory agencies, its costly nature presents a significant Wegovy manufacturer barri